Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
206.4 EUR | -0.91% | -1.57% | -13.86% |
Apr. 23 | SARTORIUS STEDIM BIOTECH : Barclays reaffirms its Neutral rating | ZD |
Apr. 22 | Sartorius Stedim: in the red with brokerage comments | CF |
Sales 2024 * | 2.94B 3.15B | Sales 2025 * | 3.35B 3.59B | Capitalization | 20.27B 21.71B |
---|---|---|---|---|---|
Net income 2024 * | 343M 367M | Net income 2025 * | 459M 492M | EV / Sales 2024 * | 7.66 x |
Net Debt 2024 * | 2.27B 2.43B | Net Debt 2025 * | 2.15B 2.31B | EV / Sales 2025 * | 6.69 x |
P/E ratio 2024 * |
57.7
x | P/E ratio 2025 * |
41.7
x | Employees | 10,493 |
Yield 2024 * |
0.36% | Yield 2025 * |
0.53% | Free-Float | 31.97% |
Latest transcript on Sartorius Stedim Biotech
1 day | -0.19% | ||
1 week | -16.21% | ||
Current month | -21.19% | ||
1 month | -25.61% | ||
3 months | -5.87% | ||
6 months | +18.55% | ||
Current year | -13.03% |
Managers | Title | Age | Since |
---|---|---|---|
René Fáber
CEO | Chief Executive Officer | 48 | 19-03-25 |
Chairman | 59 | 07-06-28 | |
Chief Tech/Sci/R&D Officer | 59 | 09-04-28 |
Members of the board | Title | Age | Since |
---|---|---|---|
Henri Riey
BRD | Director/Board Member | 62 | 07-06-28 |
Chairman | 59 | 07-06-28 | |
Susan Dexter
BRD | Director/Board Member | 67 | 15-04-06 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.42% | 18 M€ | +3.04% | - | |
0.35% | 5 M€ | +4.56% |
Date | Price | Change | Volume |
---|---|---|---|
24-04-25 | 206.4 | -0.91% | 10 965 |
24-04-24 | 208.3 | -0.19% | 76,624 |
24-04-23 | 208.7 | +6.21% | 106,382 |
24-04-22 | 196.5 | -2.04% | 113,309 |
24-04-19 | 200.6 | -4.29% | 169,509 |
Real-time Euronext Paris, April 24, 2024 at 11:35 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-13.03% | 21.66B | |
-2.89% | 185B | |
-2.43% | 107B | |
-4.10% | 67.55B | |
+11.10% | 54.6B | |
+15.86% | 47.42B | |
+4.03% | 42.24B | |
+9.55% | 28.24B | |
+1.85% | 26.42B | |
+12.53% | 25.66B |
- Stock Market
- Equities
- DIM Stock